Arbutus Biopharma Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arbutus Biopharma Corporation
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.
The deal gives Medtronic the exclusive right to acquire Half Moon Medical, a start-up developing a mitral valve repair system to compete with Abbott’s MitraClip.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Genevant Sciences
- Inex Pharmaceuticals Corporation
- OnCore Biopharma, Inc, (Enantigen Therapeutics, Inc.)
- Tekmira Pharmaceuticals Corporation (TKMR)
- Protiva Biotherapeutics Inc.